NCT02969798View on ClinicalTrials.gov

Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)

NARecruitingINTERVENTIONAL
Enrollment

700

Participants

Timeline

Start Date

January 1, 2014

Primary Completion Date

December 31, 2026

Study Completion Date

July 31, 2027

Conditions
Diabetes Mellitus, Type 2Impaired Glucose Tolerance (IGT)Impaired Fasting Glucose (IFG)
Interventions
DRUG

Dapagliflozin

10mg/day

DRUG

Saxagliptin

5mg/day

DRUG

Pioglitazone

the dose will increase from 15 mg/day to 30 mg/day at month two

DRUG

Metformin

starting at 1000 mg/day and increased to 2000 mg/day at month 2.

Trial Locations (1)

78229

RECRUITING

The University of Texas Health Science Center at San Antonio, San Antonio

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

American Diabetes Association

OTHER

collaborator

AstraZeneca

INDUSTRY

collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

The University of Texas Health Science Center at San Antonio

OTHER